Correlation Between Nottingham Prognostic Index and Adjuvant! Online Prognostic Tools in Patients With Early-Stage Breast Cancer in Mid-Western Ireland

Quintyne, Keith Ian; Woulfe, Bernie; Coffey, J. Calvin; Gupta, Rajnish K.

doi:10.1016/j.clbc.2013.02.011

Cited by 18 publications

(24 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Finally, our study showed the ability of NPI to identify six classes of patients with distinct outcome discriminating between those with good and poor prognosis ( P <0.001; Figure 2). However, NPI significantly underestimated 10-year OS ( P <0.001): yet, it should be noted that we observed higher survival rates in young breast cancer patients as compared with what was previously presented in older women for the six classes of NPI (Quintyne et al , 2013), particularly for the two moderate groups and, above all, for the two poor prognostic groups (Supplementary Table A1). …”

Section: Discussionsupporting

confidence: 46%

“…The numeric score obtained was used to stratify patients in risk categories. The following six risk categories with the respective likely predicted 10-year OS were considered (Quintyne et al , 2013): excellent, good, moderate group 1, moderate group 2, poor and very poor (Supplementary Table A1). No DFS estimates for the different categories of NPI were available in the literature.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients

et al. 2016

View full text Add to dashboard Cite

Background:Limited data are available on the prognostic performance of Adjuvant! Online (AOL) and Nottingham Prognostic Index (NPI) in young breast cancer patients.Methods:This multicentre hospital-based retrospective cohort study included young (⩽40 years) and older (55–60 years) breast cancer patients treated from January 2000 to December 2004 at four large Belgian and Italian institutions. Predicted 10-year overall survival (OS) and disease-free survival (DFS) using AOL and 10-year OS using NPI were calculated for every patient. Tools ability to predict outcomes (i.e., calibration) and their discriminatory accuracy was assessed.Results:The study included 1283 patients, 376 young and 907 older women. Adjuvant! Online accurately predicted 10-year OS (absolute difference: 0.7% P=0.37) in young cohort, but overestimated 10-year DFS by 7.7% (P=0.003). In older cohort, AOL significantly underestimated both 10-year OS and DFS by 7.2% (P<0.001) and 3.2% (P=0.04), respectively. Nottingham Prognostic Index significantly underestimated 10-year OS in both young (8.5% P<0.001) and older (4.0% P<0.001) cohorts. Adjuvant! Online and NPI had comparable discriminatory accuracy.Conclusions:In young breast cancer patients, AOL is a reliable tool in predicting OS at 10 years but not DFS, whereas the performance of NPI is sub-optimal.

show abstract

Section: Discussionsupporting

confidence: 46%

Section: Methodsmentioning

confidence: 99%

The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Its use was validated in 4083 Canadian women [36]. However, validation studies of British [37] and Irish [38] women showed that it significantly over-estimated survival. Adjuvant!…”

Section: Cdsss For Treatment Decisions In Breast Cancermentioning

confidence: 99%

Clinical Decision Support Systems in Breast Cancer: A Systematic Review

Mazo

Kearns

Mooney

et al. 2020

Cancers

View full text Add to dashboard Cite

Breast cancer is the most frequently diagnosed cancer in women, with more than 2.1 million new diagnoses worldwide every year. Personalised treatment is critical to optimising outcomes for patients with breast cancer. A major advance in medical practice is the incorporation of Clinical Decision Support Systems (CDSSs) to assist and support healthcare staff in clinical decision-making, thus improving the quality of decisions and overall patient care whilst minimising costs. The usage and availability of CDSSs in breast cancer care in healthcare settings is increasing. However, there may be differences in how particular CDSSs are developed, the information they include, the decisions they recommend, and how they are used in practice. This systematic review examines various CDSSs to determine their availability, intended use, medical characteristics, and expected outputs concerning breast cancer therapeutic decisions, an area that is known to have varying degrees of subjectivity in clinical practice. Utilising the methodology of Kitchenham and Charter, a systematic search of the literature was performed in Springer, Science Direct, Google Scholar, PubMed, ACM, IEEE, and Scopus. An overview of CDSS which supports decision-making in breast cancer treatment is provided along with a critical appraisal of their benefits, limitations, and opportunities for improvement.

show abstract

“…Indeed, the overall validity of clinicopathological scoring systems in heterogenous cohorts has been questioned [19][20][21][22]. A study by Plakhins et al showed overall and breast cancer-specific survival obtained from PREDICT was significantly lower than the observed survival of the study population [19], while Quintyne et al demonstrated that NPI also underestimates overall survival [19].…”

Section: Discussionmentioning

confidence: 99%

The Utility of Oncotype DX for Adjuvant Chemotherapy Treatment Decisions in Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Node-negative Breast Cancer

Rizki¹,

Hillyar²,

Abbassi³

et al. 2020

Cureus

View full text Add to dashboard Cite

Breast cancer is the most common cancer diagnosis in the UK. Recently, there has been a reduction in breast cancer-specific mortality and recurrence attributed, in part, to the delivery of adjuvant chemotherapy. The National Institute for Health and Care Excellence (NICE) recommends the use of genetic profiling with Oncotype DX (ODX) to guide decisions to offer adjuvant chemotherapy after surgery in intermediate-risk early breast cancer patients. This study aimed to evaluate the utility of ODX testing in routine clinical practice in a National Health Service (NHS) hospital. Methods Consecutive early breast cancer patients, identified through the multidisciplinary team (MDT) records, treated in our institution over 12 months (October 2017-September 2018) were included. PREDICT and Nottingham prognostic index (NPI) scores (from online clinicopathological recurrence risk tools) were calculated for each patient, and ODX data obtained through Genomic Health, Inc. (Redwood City, California). Patients were divided into two groups, those that underwent ODX testing (ODX group) and those that did not (non-ODX group). Descriptive statistics were used to analyse patient and tumour characteristics. The Gaussian distribution of each data set was assessed using the Anderson-Darling test. For comparisons between patient groups, the non-parametric equivalent of the two-tailed t-test (Mann-Whitney) was used. Dichotomous variables (e.g. chemotherapy decisions) were compared using chi-squared tests. Results One-hundred thirty-three patients (mean age 62 years) treated for 152 early breast cancers, were included in the final analysis. Breast cancers in the ODX group were of greater median tumour size (24 vs 16 mm; P<0.0001) and higher median tumour grade (3 vs 2; P<0.0001). PREDICT scores (3 vs 1, P<0.0001) and NPI scores (3.40 vs 2.30, P<0.0001) for the ODX group were also significantly higher than the non-ODX group. A greater proportion of patients were offered chemotherapy in the ODX group (39.9% vs 6.9%, P<0.001). However, for the PREDICTcalculated intermediate-risk patients, ODX testing resulted in a lower proportion of patients being offered chemotherapy compared to the intermediate-risk patients who were not 1 2 3 3

show abstract

Correlation Between Nottingham Prognostic Index and Adjuvant! Online Prognostic Tools in Patients With Early-Stage Breast Cancer in Mid-Western Ireland

Cited by 18 publications

References 17 publications

The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients

The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients

Clinical Decision Support Systems in Breast Cancer: A Systematic Review

The Utility of Oncotype DX for Adjuvant Chemotherapy Treatment Decisions in Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Node-negative Breast Cancer

Contact Info

Product

Resources

About